An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

December 27, 2027

Study Completion Date

December 27, 2028

Conditions

Renal Cell Carcinoma Stage I

Interventions

DRUG

Volonib combined with Everolimus Formation

Volonib 200mg once daily and Everolimus 5mg once daily

Trial Locations (2)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER